Predictors of psychosis remission in psychotic disorders that co-occur with substance use

Schizophrenia Bulletin

Volumn 32, Issue 4, 2006, Pages 618-625

  Caton, Carol L M ^a,b,e   Hasin, Deborah S ^a,b   Shrout, Patrick E ^c   Drake, Robert E ^d   Dominguez, Boanerges ^b   Samet, Sharon ^a   Schanzer, Bella ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Mailman School of Public Health   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e NONE   (United States)

Author keywords

Outcome; Primary psychosis; Substance induced psychosis

Indexed keywords

ADULT; ARTICLE; AWARENESS; CHI SQUARE TEST; COMORBIDITY; CONFIDENCE INTERVAL; DISEASE SEVERITY; EMERGENCY TREATMENT; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; REMISSION; SCALE TO ASSESS UNAWARENESS OF MENTAL DISORDERS; STATISTICAL MODEL; SUBSTANCE ABUSE; SYMPTOM;

EID: 33748773072     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbl007     Document Type: Article

References (45)

1. Strakowski SM, McElroy SL, Keck PE, West SA. The effects of antecedent substance abuse on the development of first-episode psychotic mania. J Psychiatr Res. 1996;30:59-68.
2. Kessler RC. Epidemiology of psychiatric comorbidity. In: Tsuang MT, Tohen M, Zahner GEP, eds. Textbook of Psychiatric Epidemiology. New York, NY: Wiley-Liss; 1995:179-197.
3. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511-2518.
4. Negrete JC. Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry. 2003;48:14-21.
5. Jablensky A, McGrath J, Herrman H, et al. Psychotic disorders in urban areas: an overview of the Study of Low Prevalence Disorders. Aust N Z J Psychiatry. 2000;34:221-236.
6. Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry. 1999;174:150-153.
7. Drake RE, Wallach MA. Substance abuse among the chronic mentally ill. Hosp Community Psychiatry. 1989;40:1041-1046.
8. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999; 35:S93-S100.
9. Kovasznay B, Bromet EJ, Schwartz JE, Ram R, Lavelle J, Brandon L. Substance use and onset of psychotic illness. Hosp Community Psychiatry. 1993;4:567-571.
10. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller AD, Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull. 1997;23:195-201.
11. Steadman HJ, Mulvey EP, Monahan J, et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry. 1998;55:393-401.
12. Drake RE, Wallach MA, Hoffman JS. Housing instability and homelessness among aftercare patients of an urban state hospital. Hosp Community Psychiatry. 1989;40:46-51.
13. Caton CLM, Shrout PE, Dominguez B, Eagle PF, Opler LA, Cournos F. Risk factors for homelessness among women with schizophrenia. Am J Public Health. 1995;85:1153-1156.
14. Mendoza R, Miller BL, Mena I. Emergency room evaluation of cocaine-associated neuropsychiatric disorders. In: Galanter M, ed. Recent Developments in Alcoholism: Alcohol and Cocaine: Similarities and Differences. Vol 10. New York, NY: Plenum Press; 1992:73-86.
15. Boutros N, Bowers MB. Chronic substance-induced psychotic disorders: state of the literature. J Neuropsychiatry. 1996;8:262-269.
16. Bromet EJ, Jandorf L, Fennig S, et al. The Suffolk County Mental Health Project: demographic, pre-morbid and clinical correlates of six-month outcome. Psychol Med. 1996;26: 953-962.
17. Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
18. Keshavan MS, Haas G, Miewald J, et al. Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. Schizophr Bull. 2003;29:757-769.
19. Goldstein JM, Tsuang MT. Gender and schizophrenia: an introduction and synthesis of findings. Schizophr Bull. 1990;16:179-183.
20. Angermeyer MC, Kuhn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull. 1990;16:293-307.
21. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003;28(suppl 2):17-54.
22. Hogarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409-1416.
23. Smith TE, Hull JW, Huppert JD, Silverstein SM, Anthony DT, McClough JF. Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients. J Psychiatr Res. 2004;38:169-176.
24. McGlashan T. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course. Biol Psychiatry. 1999;46:899-907.
25. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003;33:97-110.
26. Addington J, Van Mastrigt S, Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol Med. 2004;34:277-284.
27. Melle I, Larsen TK, Haahr U, et al. Reducing the duration of untreated first-episode psychosis. Arch Gen Psychiatry. 2004;61:143-150.
28. Caton CLM, Drake RE, Hasin DS, et al. Differences between early phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Arch Gen Psychiatry. 2005;62:137-145.
29. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry. 1996;153:1195-1201.
30. Hasin D, Samet S, Nunes E, Meydan J, Matseaone K, Waxman R. Diagnosis of comorbid psychiatric disorders in substance users assessed with the psychiatric research interview for substance and mental disorders for DSM-IV. Am J Psychiatry. 2006;163:689-696.
31. Torrens M, Serrano D, Astais M, Perez-Dominguez G, Martin-Santos R. Diagnosing psychiatric comorbidity in substance abusers. Validity of the Spanish versions of Psychiatric Research Interview for Substance and Mental Disorders (PRISM-IV) and the Structured Clinical Interview for DSM-IV (SCID-IV). Am J Psychiatry. 2004;161:1231-1237.
32. Caton CLM. The Community Care Schedule. New York, NY: State Psychiatric Institute; 1997.
33. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale Manual. Toronto, Canada: Multi-Health Systems, Inc.; 1992.
34. Cannon-Spoor E, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in schizophrenia. Schizophr Bull. 1982; 8:470-484.
35. Amador XF, Strauss DH, Yale S, Gorman JM, Endicott J. The assessment of insight in psychosis. Am J Psychiatry. 1993;150:873-978.
36. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied Regression Analysis and Other Multivariate Methods. 3rd ed. New York, NY: Duxbury Press; 1998.
37. Caton CLM, Hasin DS, Shrout PE, et al. The stability of DSM-IV diagnoses of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses on one-year follow-up. Br J Psychiatry. In press.
38. Vaillant GE. A 10-year follow-up of remitting schizophrenics. Schizophr Bull. 1978;4:78-85.
39. Spring BJ, Zubin J. Attention and information processing as indicators of vulnerability to schizophrenic episodes. J Psychiatr Res. 1978;14:289-301.
40. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57:1117-1127.
41. Angrist B. Amphetamine psychosis: clinical variations of the syndrome. In: Cho AK, Segal DS, eds. Amphetamine and Its Analogs. New York, NY: Academic Press; 1994:387-414.
42. Bowers MB, Swigar ME. Vulnerability to psychosis associated with hallucinogen use. Psychiatry Res. 1983;9:91-97.
43. Satel SL, Edell WS. Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry. 1991;148:1708-1711.
44. Wyatt RJ, Henter ID. The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res. 1998;32:169-177.
45. McGorry PD. Value of early intervention in psychosis. Br J Psychiatry. 2004;185:172.